# A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

> **NCT06980480** · PHASE3 · RECRUITING · sponsor: **Takeda** · enrollment: 183 (estimated)

## Conditions studied

- Multiple Myeloma
- Secondary Immunodeficiency

## Interventions

- **BIOLOGICAL:** IGI, 10%

## Key facts

- **NCT ID:** NCT06980480
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-14
- **Primary completion:** 2028-09-11
- **Final completion:** 2028-09-11
- **Target enrollment:** 183 (ESTIMATED)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06980480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06980480, "A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06980480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*